Evaluation of brain natriuretic peptide levels in hyperthyroidism and hypothyroidism

Journal of the National Medical Association

Volumn 100, Issue 4, 2008, Pages 401-405

  Ertugrul, Derun Taner ^a   Gursoy, Alptekin ^b   Sahin, Mustafa ^b   Unal, Asli Dogruk ^b   Pamuk, Baris ^b   Berberoglu, Zehra ^b   Ayturk, Semra ^b   Tutuncu, Neslihan Bascil ^a   Demirag, Nilgun Guvener ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b Division of Endocrinology and Metabolism ^*

Author keywords

Heart; Thyroid

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THYROID FUNCTION;

EID: 42349093588     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31272-4     Document Type: Chapter

References (22)

1. Kangawa K, Fukuda A, Minamino N, et al. Purification and complete amino acid sequence of beta-rat atrial natriuretic polypeptide (beta-rANP) of 5000 daltons. Biochem Biophys Res Commun. 1984;119:933-940.
2. Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature. 1988;332:78-81.
3. Hosoda K, Nakao K, Mukoyama M, et al. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension. 1991;17:1152-1155.
4. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203.
5. Edwards BS, Zimmerman RS, Schwab TR, et al. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 1988;62:191-195.
6. Bruneau BG, Piazza LA, de Bold AJ. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol. 1997;273:2678-2686.
7. Wiese S, Breyer T, Dragu A, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation. 2000;102:3074-3079.
8. Mizuno Y, Yoshimura M, Harada E, et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol. 2000; 86:1036-1040.
9. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature. 1986;324:473-476.
10. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
11. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
12. Nilsson JC, Groenning BA, Nielsen G, et al. Left ventricular remodelling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. Am Heart J. 2002;143:696-702.
13. Kohno M, Horio T, Yasunari K, et al. Stimulation of brain natriuretic peptide release from the heart by thyroid hormone. Metabolism. 1993;42:1059-1064.
14. Schultz M, Faber J, Kistorp C, et al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf). 2004;60:54-59.
15. Christ-Crain M, Morgenthaler NG, Meier C, et al. Pro-A-type and N-terminal pro-B-type natriuretic peptides in different thyroid function states. Swiss Medical Weekly. 2005;135:549-554.
16. Wei T, Zeng C, Tian Y, et al. B-type natriuretic peptide in patients with clinical hyperthyroidism. J Endocrinol Invest. 2005;28:8-11.
17. Liang F, Webb P, Marimuthu A, et al. Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes. J Biol Chem. 2003;278:15073-15083.
18. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85:4701-4705.
19. Smit JW, Eustatia-Rutten CF, Corssmit EP, et al. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2005;90:6041-6047.
20. Faber J, Wiinberg N, Schiffer S, et al. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol. 2001;145:391-396.
21. Sgarbi JA, Villaca FG, Garbeline B, et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab. 2003;88:1672-1677.
22. Faber J, Wiinberg N, Schiffer S, et al. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol. 2001;145:391-396.